<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns="http://purl.org/rss/1.0/"
   xmlns:dc="http://purl.org/dc/elements/1.1/"
   xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
   xmlns:dcterms="http://purl.org/dc/terms/"

>
<channel rdf:about="http://www.citeulike.org/about">
<pubDate>Sat, 26 Jul 2008 04:34:13 BST</pubDate>


	<title>CiteULike: AlfonsoVicenteSuarez's th2-tumor</title>
	<description>CiteULike: AlfonsoVicenteSuarez's th2-tumor</description>


	<link>http://www.citeulike.org/user/AlfonsoVicenteSuarez/tag/th2-tumor</link>
	<dc:publisher>CiteULike.org</dc:publisher>
	<dc:language>en-gb</dc:language>
	<dc:rights>Copyright &#169; 2004-2008 citeulike.org</dc:rights>
	<items>
    <rdf:Seq>
        <rdf:li rdf:resource="http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1423266"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1423239"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1375862"/>

	</rdf:Seq>
	</items>
	</channel>


<item rdf:about="http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1423266">
    <title>A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma</title>
    <link>http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1423266</link>
    <description>&lt;i&gt;J Immunol, Vol. 160, No. 12. (15 June 1998), pp. 5869-5873.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;The role of Th2 cells and the cytokines produced by these cells on experimental pulmonary metastasis of B16 melanoma was investigated in a murine model implanted with high metastatic (B16F10) or low metastatic (B16F1) melanoma cells. An average of 250 colonies of metastasis in the lungs was counted in mice (BF10 mice) at 14 days after the inoculation of 2 x 105 B16F10 cells/mouse, while &#60;20 colonies were detected in mice (BF1 mice) inoculated with the same number of B16F1 cells. CD4+CD11b+TCR-alphabeta+ T cells (BF10-Th2 cells) were produced in the spleens of BF10 mice, while these cells were not detected in BF1 mice. The BF10-Th2 cells produced IL-4 and IL-10 into culture fluids when stimulated in vitro with anti-CD3 mAb. However, IL-2 and IFN-gamma were not produced. The level of a pulmonary metastasis in BF1 mice increased to the level observed in BF10 mice, when BF10-Th2 cells were adoptively transferred to BF1 mice. Also, an increase in the number of pulmonary melanoma was demonstrated in BF1 mice treated with 10 microg/kg murine rIL-4. The level of pulmonary metastasis in BF10 mice or in BF1 mice inoculated with BF10-Th2 cells decreased to the level observed in BF1 mice when mice were treated with an anti-IL-4 mAb at a dose of 250 microg/kg on days 1, 3, and 5 after tumor inoculation. These results suggest that the severity of pulmonary metastasis in mice receiving B16 melanoma cells is strongly influenced by the IL-4 released from tumor-associated Th2 cells.</description>
    <dc:title>A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma</dc:title>

    <dc:creator>Makiko Kobayashi</dc:creator>
    <dc:creator>Hiroyuki Kobayashi</dc:creator>
    <dc:creator>Richard Pollard</dc:creator>
    <dc:creator>Fujio Suzuki</dc:creator>
    <dc:source>J Immunol, Vol. 160, No. 12. (15 June 1998), pp. 5869-5873.</dc:source>
    <dc:date>2007-06-29T16:02:27-00:00</dc:date>
    <prism:publicationYear>1998</prism:publicationYear>
    <prism:publicationName>J Immunol</prism:publicationName>
    <prism:volume>160</prism:volume>
    <prism:number>12</prism:number>
    <prism:startingPage>5869</prism:startingPage>
    <prism:endingPage>5873</prism:endingPage>
    <prism:category>th2-tumor</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1423239">
    <title>Distinct Role of Antigen-specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication In Vivo</title>
    <link>http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1423239</link>
    <description>&lt;i&gt;J. Exp. Med., Vol. 190, No. 5. (6 September 1999), pp. 617-628.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;The role of T helper type 1 (Th1) and Th2 cells in tumor immunity was investigated using Th cells induced from ovalbumin (OVA)-specific T cell receptor transgenic mice. Although Th1 cells exhibited stronger cytotoxicity than Th2 cells, both cell types completely eradicated tumors when transferred into mice bearing A20 tumor cells transfected with the OVA gene (A20-OVA). Th1 cells eradicated the tumor mass by inducing cellular immunity, whereas Th2 cells destroyed the tumor by inducing tumor necrosis. Both Th1 and Th2 cells required CD8+ T cells to eliminate tumors, and neither of these cells were able to completely eliminate A20-OVA tumors from T and B cell-deficient RAG2-/- mice. Mice cured from tumors by Th1 and Th2 cell therapy rejected A20-OVA upon rechallenge, but CD8+ cytotoxic T lymphocytes were induced only from spleen cells prepared from cured mice by Th1 cell therapy. Moreover, we demonstrated that Th1 and Th2 cells used distinct adhesion mechanisms during tumor eradication: the leukocyte function-associated antigen (LFA)-1-dependent cell-cell adhesion step was essential for Th1 cell therapy, but not for Th2 cell therapy. These findings demonstrated for the first time the distinct role of antigen-specific Th1 and Th2 cells during eradication of established tumors in vivo. 10.1084/jem.190.5.617</description>
    <dc:title>Distinct Role of Antigen-specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication In Vivo</dc:title>

    <dc:creator>Takashi Nishimura</dc:creator>
    <dc:creator>Kenji Iwakabe</dc:creator>
    <dc:creator>Masashi Sekimoto</dc:creator>
    <dc:creator>Yasushi Ohmi</dc:creator>
    <dc:creator>Takashi Yahata</dc:creator>
    <dc:creator>Minoru Nakui</dc:creator>
    <dc:creator>Takehito Sato</dc:creator>
    <dc:creator>Sonoko Habu</dc:creator>
    <dc:creator>Hiroyuki Tashiro</dc:creator>
    <dc:creator>Marimo Sato</dc:creator>
    <dc:creator>Akio Ohta</dc:creator>
    <dc:identifier>doi:10.1084/jem.190.5.617</dc:identifier>
    <dc:source>J. Exp. Med., Vol. 190, No. 5. (6 September 1999), pp. 617-628.</dc:source>
    <dc:date>2007-06-29T15:56:45-00:00</dc:date>
    <prism:publicationYear>1999</prism:publicationYear>
    <prism:publicationName>J. Exp. Med.</prism:publicationName>
    <prism:volume>190</prism:volume>
    <prism:number>5</prism:number>
    <prism:startingPage>617</prism:startingPage>
    <prism:endingPage>628</prism:endingPage>
    <prism:category>th2-tumor</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1375862">
    <title>Th2-mediated anti-tumour immunity: friend or foe?</title>
    <link>http://www.citeulike.org/user/AlfonsoVicenteSuarez/article/1375862</link>
    <description>&lt;i&gt;Tissue Antigens, Vol. 70, No. 1. (July 2007), pp. 1-11.&lt;/i&gt;</description>
    <dc:title>Th2-mediated anti-tumour immunity: friend or foe?</dc:title>

    <dc:creator>Ellyard</dc:creator>
    <dc:creator></dc:creator>
    <dc:creator>Simson</dc:creator>
    <dc:creator></dc:creator>
    <dc:creator>Parish</dc:creator>
    <dc:creator></dc:creator>
    <dc:identifier>doi:10.1111/j.1399-0039.2007.00869.x</dc:identifier>
    <dc:source>Tissue Antigens, Vol. 70, No. 1. (July 2007), pp. 1-11.</dc:source>
    <dc:date>2007-06-10T11:35:51-00:00</dc:date>
    <prism:publicationYear>2007</prism:publicationYear>
    <prism:publicationName>Tissue Antigens</prism:publicationName>
    <prism:issn>0001-2815</prism:issn>
    <prism:volume>70</prism:volume>
    <prism:number>1</prism:number>
    <prism:startingPage>1</prism:startingPage>
    <prism:endingPage>11</prism:endingPage>
    <prism:publisher>Blackwell Publishing</prism:publisher>
    <prism:category>th2-tumor</prism:category>
</item>



</rdf:RDF>

